Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study ; volume:8 ; number:1 ; day:13 ; month:8 ; year:2008 ; pages:1-10 ; date:12.2008
BMC cancer ; 8, Heft 1 (13.8.2008), 1-10, 12.2008
- Urheber
-
Razis, Evangelia
- Beteiligte Personen und Organisationen
-
Briasoulis, Evangelos
Brettu, Elenē
Skarlos, Dimosthenis V.
Papamichael, Dimitrios
Kostopoulos, Ioannis
Samantas, Epaminontas
Xanthakis, Ioannis
Bobos, Mattheos
Galanidi, Eleni
Bai, Maria
Gikonti, Ioanna
Koukouma, Alona
Kafiri, Georgia
Papakostas, Pavlos
Kalogeras, Konstantine T.
Kosmidis, Paris
Fountzilas, George
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-8-234
- URN
-
urn:nbn:de:1111-2016030346142
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.1970, 07:27 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Razis, Evangelia
- Briasoulis, Evangelos
- Brettu, Elenē
- Skarlos, Dimosthenis V.
- Papamichael, Dimitrios
- Kostopoulos, Ioannis
- Samantas, Epaminontas
- Xanthakis, Ioannis
- Bobos, Mattheos
- Galanidi, Eleni
- Bai, Maria
- Gikonti, Ioanna
- Koukouma, Alona
- Kafiri, Georgia
- Papakostas, Pavlos
- Kalogeras, Konstantine T.
- Kosmidis, Paris
- Fountzilas, George
- SpringerLink (Online service)
Ähnliche Objekte (12)
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
Right- and left-sided colorectal cancers respond differently to cetuximab
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer
Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
Can we accurately report PTEN status in advanced colorectal cancer?
Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts
Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
Right- and left-sided colorectal cancers respond differently to cetuximab
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer
Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
Can we accurately report PTEN status in advanced colorectal cancer?
Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts
Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
Right- and left-sided colorectal cancers respond differently to cetuximab
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer
Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
Can we accurately report PTEN status in advanced colorectal cancer?
Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts
Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer